Literature DB >> 3190191

Concentrations of erythromycin, 2'-acetyl erythromycin, and their anhydro forms in plasma and tonsillar tissue after repeated dosage of erythromycin stearate and erythromycin acistrate.

A Gordin1, P T Männistö, R Antikainen, S Savolainen, J Ylikoski, P Kokkonen, V Rauramaa.   

Abstract

The concentrations of erythromycin, 2'-acetylerythromycin (2'-AE) and their anhydro forms in plasma and tonsillar tissue were analyzed after a 3-day repeated-dosage regimen of erythromycin stearate (ES; 500 mg twice a day [b.i.d]) and erythromycin acistrate (EA), a new erythromycin prodrug, at two doses (400 and 500 mg b.i.d.). The tonsils of 40 patients were removed at 112 to 329 min after intake of the last dose. Blood samples were collected at the time of tonsillectomy and at 0, 2, and 6 h after the last dose. At all time points, EA produced severalfold more total antibiotic (erythromycin + 2'-AE) concentrations in plasma compared with ES. There were two nonabsorbers in the ES group, but none in the two EA groups. The mean total antibiotic levels in tonsillar tissue after EA treatment exceeded the levels after treatment with ES by a factor of 3 (for EA at 400 mg b.i.d.) and 4.5 (for EA at 500 mg b.i.d.). The ratios of erythromycin concentration in tonsil to that in plasma at the time of tissue removal were quite similar for all groups (means, 0.51 to 0.54). In the EA groups, 2 of 26 (8%) patients had no measurable erythromycin in the tonsillar tissue samples, whereas in the ES group, 3 of 14 (21%) patients had no measurable erythromycin in the same tissue. The degree of hydrolysis of 2'-AE to erythromycin was about 25% in plasma at the time of tonsillectomy for both EA groups and about 40% in tonsillar tissue. There were negligible amounts of anhydro forms in plasma after EA administration, whereas in the ES group, anhydroerythromycin levels were, from time to time, even higher than erythromycin levels. Very high levels of anhydro forms were detected in tonsillar tissue after ES treatment, whereas only low levels were found after EA administration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190191      PMCID: PMC172336          DOI: 10.1128/AAC.32.7.1019

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Gastric acid inactivation of erythromycin stearate in solid dosage forms.

Authors:  B G Boggiano; M Gleeson
Journal:  J Pharm Sci       Date:  1976-04       Impact factor: 3.534

2.  Concentrations of erythromycin in serum and tonsil: comparison of the estolate and ethyl succinate suspensions.

Authors:  C M Ginsburg; G H McCracken; M C Culbertson
Journal:  J Pediatr       Date:  1976-12       Impact factor: 4.406

3.  Penetration of erythromycin into tonsillar tissue.

Authors:  M Falchi; F Teodori; A Carraro; C Cioce; F Scaglione; P C Braga; F Fraschini
Journal:  Curr Med Res Opin       Date:  1985       Impact factor: 2.580

4.  [Concentrations of erythromycin and amoxicillin in tonsil and sinus tissues of patients with tonsillitis and sinusitis. A comparison (author's transl)].

Authors:  H Blenk; K Simm; B Blenk; G Jahneke
Journal:  Infection       Date:  1982       Impact factor: 3.553

5.  The penetration of erythromycin into Waldeyer's ring--tonsil and adenoid tissue.

Authors:  L Sundberg; T Edén; S Ernstson
Journal:  Infection       Date:  1982       Impact factor: 3.553

6.  Fate of single oral doses of erythromycin acistrate, erythromycin stearate and pelleted erythromycin base analysed by mass-spectrometry in plasma of healthy human volunteers.

Authors:  P T Männistö; J Taskinen; P Ottoila; A Solkinen; A Vuorela; S Nykänen
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

7.  Tonsillar penetration of erythromycin and its 2'-acetyl ester in patients with chronic tonsillitis.

Authors:  S Savolainen; P T Männistö; A Gordin; R Antikainen; H Haataja; R K Tuominen; J Ylikoski
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

8.  Hydrolysis of 2'-esters of erythromycin.

Authors:  J Taskinen; P Ottoila
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

9.  Determination of 2'-acetyl erythromycin and erythromycin in human tonsil tissue by HPLC with coulometric detection.

Authors:  H Haataja; P Kokkonen
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

10.  Antibiotic concentration in suction skin blister fluid and saliva after repeated dosage of erythromycin acistrate and erythromycin base.

Authors:  R K Tuominen; P T Männistö; A Solkinen; A Vuorela; P Pohto; H Haataja
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

View more
  4 in total

1.  Effect of erythromycin on the oro-caecal transit time in man.

Authors:  J Lehtola; P Jauhonen; A Kesäniemi; R Wikberg; A Gordin
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Optimum treatment of streptococcal pharyngitis.

Authors:  F Scaglione; G Demartini; M M Arcidiacono; J P Pintucci
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

3.  Amphiphilic erythromycin-lipoamino acid ion pairs: characterization and in vitro microbiological evaluation.

Authors:  Rosario Pignatello; Annalisa Mangiafico; Barbara Ruozi; Giovanni Puglisi; Pio Maria Furneri
Journal:  AAPS PharmSciTech       Date:  2011-04-09       Impact factor: 3.246

4.  Bioavailability of erythromycin acistrate from hard gelatin capsules containing sodium bicarbonate.

Authors:  M Marvola; S Nykänen; M Nokelainen
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.